Skip to main content
. 2015 Jun 10;6(26):22666–22679. doi: 10.18632/oncotarget.4433

Figure 6. Nutlin-3 induced a strong G2/M phase arrest in combination with CDDP in the p53 wild type cell line A549.

Figure 6

A. Relative mRNA expression levels of p53's transcription target p21. Cells were treated with either 2 μM CDDP; 5 μM, 10 μM or 25 μM Nutlin-3, or a sequential (CDDP –> Nutlin)/simultaneous combination therapy of both drugs for 24 hours. B. Corresponding p21 protein levels, β-actin was used as internal standard. C. Cell cycle distribution of treated cells. Cells were stained with PI and DNA content was measured by flowcytometric analysis. Cells were divided in 3 groups: G1 phase (2n); S-phase (2n-4n); and G2/M phase (4n). (*p < 0.05: significant diffence compared to 0 μM CDDP; **p < 0.05: significant difference compared to 2 μM CDDP).